Industry-Supported Sessions

*All times are listed in EDT (UTC-4); all information as of press time*

Saturday, October 10

0800–0915
Symposium: Multidisciplinary Management of Early Stage Bladder Cancer

Chair: Peter Black, Canada
Faculty: Jürgen E. Gschwend, Germany
Shilpa Gupta, United States
Srikala Sridhar, Canada
Tilman Todenhöfer, Germany

At the end of this session, attendees will be able to:
• Review the most updated guidelines on NMBIC and MIBC
• Recognize the importance of risk stratification in the treatment decision-making for NMIBC and MIBC
• Review potential biomarkers to predict response to chemotherapy and immunotherapy in MIBC
• Analyze key data from clinical trials of IO and novel therapies in NMIBC, as well as emerging and combination therapies for MIBC
• Recognize the importance of a multidisciplinary team-based care planning for patients with early stage disease
• Outline immune-related adverse events and best practices for their mitigation and management

1245-1250
Welcome and Introductions
Peter Black

1250-1302
Evolving Treatment of High- Risk NMIBC
Tilman Todenhöfer, Germany

1302-1320
Case Presentation 1: BCG-unresponsive Case
Juergen Gschwend, Germany

1320-1332
New Paradigms in Multimodal Management of MIBC
Srikala Sridhar, Canada

1332-1350
Case Presentation 2: MIBC Case
Shilpa Gupta, United States

1350-1400
Take Home Messages and Wrap-Up
Peter Black

This session is supported by SIU Corporate Sponsor Bristol Myers Squibb.

1145–1300
Symposium: Up Close and Personal: Talking to your Patients about Overactive Bladder

Chair: Lysanne Campeau, Canada
Faculty: Dean Elterman, Canada
Stavros Gravas, Greece
Sender Herschorn, Canada

Case Presentations and Panel Discussion
Patient 1: Patient with OAB and LUTS secondary to benign prostatic hyperplasia
Stavros Gravas

Patient 2: Elderly woman (≥65 years) with other comorbidities (post-menopausal and estrogen-deficient case)
Sender Herschorn

Patient 3: Younger woman who is refractory to treatment
Dean Elterman

This session is supported by SIU Corporate Sponsor Astellas Pharma.

1900–2000
MC-02: MASTER CLASS: Genomic Testing and Recurrence in Prostate Cancer

Co-Chairs: Shusuke Akamatsu, Japan and Marc Dall’Era, United States
Moderator: Marc Dall’Era

At the end of this session, attendees will be able to:
• Recognize when to order genomic testing in prostate cancer treatment
• Determine who is expected to benefit from treatment with PARP inhibitors
• Explain the importance of genetic counseling
• State the current status and future prospect of liquid biopsy
Method: Lectures and discussion

1900–1912
The Role of Genomic Testing in Prostate Cancer
Vito Cucchiara, Italy

1912–1924
DNA Repair Gene Mutations and PARP Inhibitors in Prostate Cancer
Marc Dall’Era

1924–1936
Genetic Counselling in Prostate Cancer
Scott Eggener, United States

1936–1948
Liquid Biopsy in Prostate Cancer, Where Are We Now?
Shusuke Akamatsu

1948–2000
Debate and Q&A on Availability of Genetic Testing and Counselling in Each Region (USA, Italy, and
Japan, each representing North America, Europe and Asia)
All

This session is made possible by an unrestricted educational grant from Takeda Pharmaceutical Company

Sunday, October 11

0600–0700
IC-06: INSTRUCTIONAL COURSE 06: Urethral Stricture Surgery

Chair: Sanjay Kulkarni, India

0600-0615
Penile Urethra Simple and Complex
Guido Barbagli, Italy

0615-0620
Discussion and Questions
Guido Barbagli, Italy

0620-0635
Bulbar Urethra Anastomotic, Dorsal and Ventral BMG, Non-Transection Bulbar Urethroplasty
Anthony Mundy, United Kingdom

0635-0640
Discussion and Questions
Anthony Mundy

0640-0655
Posterior Urethral Injury Acute Management and Delayed Treatment, Complex PFUI
Sanjay Kulkarni, India

0655-0700
Discussion and Questions
Sanjay Kulkarni

This session is made possible by an unrestricted educational grant provided from Sun Pharma.

1000–1045
INN: SIU INNOVATORS: Prostate Cancer Debate

Moderator: Siska van Bruwaene, Belgium

At the conclusion of this activity, participants will be able to:
• Select the correct therapeutic strategy for patients with localized prostate cancer, depending on different patient and tumor characteristics
• List the advantages and disadvantages of prostate biopsy strategies
• Explain the use of PSMA scan in different clinical settings
• List all the advantages and disadvantages of performing lymph node dissection in prostate cancer patients

This session is made possible by an unrestricted educational grant from Takeda Pharmaceutical Company.

1000-1020
1. Case Presentations: Prostate Cancer in the Elderly

1000-1001
A. Case Presentation: To Biopsy or not to Biopsy
Siska van Bruwaene

1001-1004
PRO
To be confirmed

1004-1007
CON
Laurence Klotz, Canada

1007-1008
B. Case Presentation: Surgery versus Radiotherapy

1008-1011
PRO
Shusuke Akamatsu, Japan

1011-1014
CON
Andres Hernández-Porras, Mexico

1014-1020
Discussion
All

1020-1025
Break

1025-1045
2. Case Discussion: PSMA and Lymph Nodes in Prostate Cancer

1025-1026
Case Presentation
Siska van Bruwaene

1026-1030
No Lymph Node Dissection. No PSMA
Wouter Everaert, Belgium

1030-1034
Treatment Tailored by PSMA
Renu Eapen, Australia

1034-1038
Perform Lymph Node Dissection
Karim Touijer, United States

1038-1045
Discussion
All

This session is made possible by an unrestricted educational grant from Takeda Pharmaceutical Company

1400–1530
IC-17: INSTRUCTIONAL COURSE: A Multidisciplinary Team Approach to the Treatment of Urothelial Carcinoma in the Age of Anti-PD1 Agents

Chair: Shaheen Alanee, United States

At the end of this session, attendees will be able to:
• Recognize the role of the multidisciplinary team (MDT) approach in the patient journey through treatment with immunotherapy for advanced bladder cancer
• Receive an introduction to systemic Immunotherapy in bladder cancer, Role of the MDT in identifying and managing immune-related side effects associated with anti-PD1 agents
• Understand the importance of interdisciplinary communication and education in preventing life-threatening complications
Method: Lectures and discussion

1400–1405
Course Introduction
Shaheen Alanee

1405–1425
Background on Bladder Cancer and Introduction to Anti-PD1 Agents
Shaheen Alanee

1425–1505
Benefits of MDT Approach for Patients Receiving Treatment with Anti PD Agents, and the Role of Anti-PD1 Agents in the Management of Locally Advanced and Metastatic Bladder Cancer
Petros Grivas, United States

1505–1530
Group Discussion

This session is made possible by an unrestricted educational grant from AstraZeneca.